Topics

Tucatinib Takes Step Toward EU Approval in HER2+ Breast Cancer

12:51 EST 31 Jan 2020 | OncLive

The European Medicines Agency has validated a Marketing Authorization Application for tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases, who have received ≥2 prior anti-HER2 treatment regimens.

Original Article: Tucatinib Takes Step Toward EU Approval in HER2+ Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Tucatinib Takes Step Toward EU Approval in HER2+ Breast Cancer"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...